This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Impax Laboratories, Inc.
Drug Names(s): Bupivacaine Transdermal Patch, DUR-843, IPX239, TRANSDUR-Bupivacaine
Description: TRANSDUR-Bupivacaine (DUR-843) is a transdermal pain patch. Local anesthetics such as bupivacaine block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential.
Deal Structure: ELADUR was originally developed by DURECT.
Alpharma and DURECT
In September 2008, DURECT Corporation announced that it entered into a development and license agreement with an affiliate of Alpharma granting such party the exclusive worldwide rights to develop and commercialize ELADUR, under development for the treatment of pain associated with post-herpetic neuralgia (PHN).
King and Alpharma
On September 12, 2008, King Pharmaceuticals announced that it commenced a tender offer, through a wholly owned subsidiary, to acquire all of the outstanding shares of Class A Common Stock of Alpharma for $37 per share in cash. The deal was unanimously rejected by Alpharma's board on September 26, 2008.
In November 2008, King Pharmaceuticals and Alpharma announced that the two companies signed a definitive merger agreement under which King will acquire all of the outstanding shares of Class A Common Stock of Alpharma for $37.00 per share in cash for a total equity...See full deal structure in Biomedtracker
Partners: DURECT Corporation
Additional information available to subscribers only: